# Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Study · id `cardio:ct-nct02504216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02504216](<https://clinicaltrials.gov/study/NCT02504216>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02504216

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6564 participants.

## Technical summary

Registry record NCT02504216. Randomized; quadruple masking; primary purpose prevention. Start 2015-08-18 (actual); primary completion 2019-11-27 (actual). Results posted on 2020-12-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 6564 participants (enrolled count; ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Started: 2015-08-18 (actual) (ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Primary completion: 2019-11-27 (actual) (ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Completion: 2020-01-09 (actual) (ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Results first posted: 2020-12-08 (ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Estonia; Finland; France; Germany; Hungary; Italy; Japan; Latvia; Lithuania; Netherlands; Poland; Portugal; Romania; Russia; Serbia; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02504216, source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02504216-2020-12-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
- Acronym: VOYAGER PAD
- Condition: Peripheral Artery Disease
- Intervention (Drug): Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug): Rivaroxaban-Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY
- Collaborator: Janssen Research & Development, LLC
- Collaborator class: INDUSTRY
- Collaborator: Colorado Prevention Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: Colorado Prevention Center (`cardio:org-colorado-prevention-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban in Peripheral Artery Disease after Revascularization (`cardio:pubmed-32222135`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety (`cardio:pubmed-33138628`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial (`cardio:pubmed-34010631`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial (`cardio:pubmed-34380322`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD (`cardio:pubmed-34711335`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD (`cardio:pubmed-35699170`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits (`cardio:pubmed-36470531`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD (`cardio:pubmed-41128134`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial (`cardio:pubmed-41757414`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 841e6712a185a9d24c82537994d7d78a0c3e17873d505a63b4c3d2e519f89176
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
